NHS to offer second MenB vaccine after deadly Kent outbreak
NHS Expands MenB Vaccination Effort Following Kent Outbreak
Following a meningitis B outbreak in Kent, the NHS has announced that nearly 12,000 individuals who received initial vaccinations will now be eligible for a second dose starting next week. The outbreak claimed two lives and infected 19 others, prompting a broader public health response. The second dose, which must be administered at least four weeks after the first, will be available through multiple clinics across the region.
Eligible individuals include students from university halls, attendees of a local nightclub linked to the outbreak, and certain sixth form pupils. NHS Kent and Medway confirmed that appointments will be accessible at various locations, with detailed booking instructions set to be released on Monday. The vaccine targets the majority of meningococcal group B strains prevalent in the UK, offering critical protection to those at risk.
Targeted Rollout and Expanded Eligibility
The vaccination drive initially focused on students in university residences and patrons of Club Chemistry, where the outbreak is believed to have started. Subsequently, the program broadened to encompass other sixth form students from schools or colleges with confirmed cases. Preventative antibiotics were also distributed to a larger group, with long lines forming at the University of Kent over several days.
“The outbreak represents an unprecedented situation due to the rapid spread among a significant number of people,” stated Health Secretary Wes Streeting. He emphasized the need to reassess vaccination strategies after the incident, which led to the involvement of independent experts from the Joint Committee on Vaccination and Immunisation (JCVI).
Previously, the UK introduced a routine MenB vaccination program for infants in 2015. At that time, health advisers deemed a catch-up campaign for teenagers cost-ineffective, opting instead for the MenACWY vaccine, which covers four meningitis-causing bacteria but excludes MenB. The recent Kent outbreak has prompted a review of this decision, with the potential to adjust guidelines for adolescent immunization.
